A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Contro… (NCT07043478) | Clinical Trial Compass
RecruitingNot Applicable
A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population
Canada24 participantsStarted 2025-08-05
Plain-language summary
The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is:
Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load.
Participants will \[describe the main tasks participants will be asked to consume 750 mg of Bragg Apple Cider Vinegar (ACV) liquid or water and undergo a blood draw to measure glucose, insulin, and future analysis markers.
Who can participate
Age range20 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Abdominal obesity: waist circumference \> 102 cm (40 inches) in men and \> 88 cm (35 inches) in women
✓. Low HDL-C: \< 40 mg/dL (1.03 mmol/L) in men and \< 50 mg/dL (1.29 mmol/L) in women 4. Stable body weight defined as a \<5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI) 5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 6. Agrees to comply with dietary guidelines and study requirements prior to in-clinic visits (see Section 9.1) 7. Provided voluntary, written, informed consent to participate in the study 8. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)
Exclusion criteria
✕. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
✕. Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
What they're measuring
1
The difference in the iAUC(0 - 120 min) for venous blood glucose concentration between Bragg ACV liquid and placebo following an acute carbohydrate load
✕. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
✕. Unstable metabolic disease or chronic diseases as assessed by the QI
✕. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
✕. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI